TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22882740

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (1.53 g EPA and 0.31 g DHA per 1000 kcal ME)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Corn oil supplementation (0.00 g EPA and 0.00 g DHA per 1000 kcal ME)
Number of subjects: 16
Study: 21569165

Group type: EXPERIMENTAL
Intervention: SC + CCTA
Number of subjects: 60

Group type: COMPARATOR
Intervention: SC
Number of subjects: 60
Study: 18366244

Group type: EXPERIMENTAL
Intervention: Educational outreach visits (1-hour long)
Number of subjects: 1433
Study: 16848893

Group type: EXPERIMENTAL
Intervention: r-FSH
Number of subjects: 260

Group type: COMPARATOR
Intervention: HP-uFSH
Number of subjects: 260
Study: 12603251

Group type: EXPERIMENTAL
Intervention: CSF total-tau (T-tau)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CSF phospho-tau (P-tau)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CSF A beta 42
Number of subjects: 44
Study: 11061244

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticonvulsant sodium channel blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin (anticonvulsant calcium channel blocker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tramadol (mixed opioid and monoaminergic drug)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (NMDA-antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mexiletine (antiarrhythmic sodium channel blocker)
Number of subjects: 0
Study: 9112896

Group type: EXPERIMENTAL
Intervention: Resection
Number of subjects: 14

Group type: COMPARATOR
Intervention: Drainage
Number of subjects: 14
Study: 8356370

Group type: EXPERIMENTAL
Intervention: Manual treatment with steroid injections
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional treatment (standardized conventional but optimized activating treatment)
Number of subjects: 101
Study: 3533909

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 29665493

Group type: EXPERIMENTAL
Intervention: Daily positive events
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Daily stressful events
Number of subjects: 200
Study: 27316778

Group type: EXPERIMENTAL
Intervention: 1% Tenofovir Gel
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hydroxyethyl Cellulose (HEC) - Control
Number of subjects: 24
Study: 25190226

Group type: EXPERIMENTAL
Intervention: Alogliptin and insulin
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo and insulin
Number of subjects: 179
Study: 21308859

Group type: EXPERIMENTAL
Intervention: 6-day residential course of lectures, discussions and peer groups on issues related to treatment and living with cancer
Number of subjects: 507

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 507
Study: 20029715

Group type: EXPERIMENTAL
Intervention: Errorless (EL) learning and spaced retrieval (SR)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Errorful (EF) learning paradigm
Number of subjects: 22
Study: 18669424

Group type: COMPARATOR
Intervention: D2 lymphadenectomy alone
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy plus PAND
Number of subjects: 523
Study: 16424293

Group type: EXPERIMENTAL
Intervention: Oxandrolone (10 mg twice daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 15071260

Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous heparin/oral phenprocoumon
Number of subjects: 0
Study: 10584042

Group type: EXPERIMENTAL
Intervention: Modified milk fat
Number of subjects: 21

Group type: COMPARATOR
Intervention: Regular milk fat
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nonhydrogenated margarine
Number of subjects: 21
Study: 8843558

Group type: EXPERIMENTAL
Intervention: Diet of environmentally contaminated Lake Ontario salmon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relatively uncontaminated Pacific Ocean salmon
Number of subjects: 0

Group type: COMPARATOR
Intervention: No salmon
Number of subjects: 0
Study: 1913409

Group type: EXPERIMENTAL
Intervention: Telephone reminder group
Number of subjects: 5883

Group type: EXPERIMENTAL
Intervention: Letter reminder group
Number of subjects: 5883

Group type: EXPERIMENTAL
Intervention: Physician reminder group
Number of subjects: 5883

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5883
Study: 6978871

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan
Number of subjects: 0
Study: 31952249

Group type: EXPERIMENTAL
Intervention: Synbiotic supplement containing Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium bifidum, and a galactooligosaccharide mixture; duration: 3 months.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo; duration: 3 months.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Synbiotic supplement;
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo;
Number of subjects: 20
Study: 30911782

Group type: EXPERIMENTAL
Intervention: FRAX followed by DXA screening
Number of subjects: 30719

Group type: COMPARATOR
Intervention: Usual care (opportunistic screening)
Number of subjects: 30719
Study: 29941151

Group type: EXPERIMENTAL
Intervention: ZX008 (fenfluramine hydrochloride oral solution) 0.8 mg/kg after a 10-hour overnight fast
Number of subjects: 13

Group type: COMPARATOR
Intervention: ZX008 (fenfluramine hydrochloride oral solution) 0.8 mg/kg 30 minutes after a high-fat breakfast
Number of subjects: 13
Study: 27357103

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (20,000 IU per week)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study: 25756831

Group type: EXPERIMENTAL
Intervention: FDC aclidinium 400 μg/formoterol 12 μg (ACL400/FOR12 FDC)
Number of subjects: 1692

Group type: EXPERIMENTAL
Intervention: FDC aclidinium 400 μg/formoterol 6 μg (ACL400/FOR6 FDC)
Number of subjects: 1692

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1692
Study: 21937686

Group type: EXPERIMENTAL
Intervention: Alcohol (0.08% target blood alcohol concentration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19723906

Group type: EXPERIMENTAL
Intervention: DMARD adherence measured by Compliance Questionnaire on Rheumatology (CQR)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: DMARD adherence measured by Medication Adherence Scale (MARS)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Nonadherence risk factors
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Disease duration, perceived side-effects, beliefs about necessity of medicine
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Overall nonadherence rate
Number of subjects: 228
Study: 17703139

Group type: EXPERIMENTAL
Intervention: Tolvaptan + Furosemide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tolvaptan + HCTZ
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tolvaptan alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Furosemide or HCTZ administered alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tolvaptan + Furosemide or HCTZ
Number of subjects: 12
Study: 15385638

Group type: EXPERIMENTAL
Intervention: Normal sodium intake (ad libitum)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low sodium intake (<5 g/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High sodium intake (100 mg/kg/day)
Number of subjects: 12
Study: 11430631

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid IFN-alpha (Group A)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Recombinant 2a IFN-alpha (Group B)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Recombinant 2b IFN-alpha (Group C)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Leukocyte IFN-alpha (Group D)
Number of subjects: 128
Study: 9951054

Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 0
Study: 7886394

Group type: EXPERIMENTAL
Intervention: Omeprazole plus amoxicillin (40 mg or 80 mg) for 1- or 2-week regimens
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Omeprazole plus amoxicillin
Number of subjects: 423
Study: 3061773

Group type: EXPERIMENTAL
Intervention: Thiopental anaesthesia
Number of subjects: 20
Study: 29192741

Group type: EXPERIMENTAL
Intervention: Sunitinib or pazopanib
Number of subjects: 270

Group type: COMPARATOR
Intervention: Cytoreductive nephrectomy (CN) followed by sunitinib or pazopanib
Number of subjects: 270
Study: 27517517

Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony (TGP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 25775747

Group type: EXPERIMENTAL
Intervention: Epley maneuver
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Semont maneuver
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Epley maneuver combined with Semont maneuver
Number of subjects: 150
Study: 22851113

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (goal of 90 min/wk for months 1‐3 followed by home exercise with a goal of ≥120 min/wk for months 4‐12)
Number of subjects: 2322

Group type: COMPARATOR
Intervention: Usual care (education and usual guideline‐based heart failure care)
Number of subjects: 2322

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 2322

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2322
Study: 20090337

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg) once daily for 6-8 weeks before H. pylori eradication (group A)
Number of subjects: 116

Group type: COMPARATOR
Intervention: H. pylori eradication treatment followed by lansoprazole (30 mg) for 6-8 weeks (group B)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 116
Study: 18381181

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg by mouth, 3 times per day for 4 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 16387219

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 153

Group type: COMPARATOR
Intervention: Droperidol
Number of subjects: 153
Study: 12859551

Group type: EXPERIMENTAL
Intervention: Guidelines strategy group (ebastine, triamcinolone acetonide, and/or nedocromil sodium)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Free-choice treatment group
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Guidelines strategy group
Number of subjects: 465
Study: 10393676

Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/d)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Aspirin (250 mg/d)
Number of subjects: 211
Study: 9122463

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 130

Group type: COMPARATOR
Intervention: Scopolamine methylbromide (SMB)
Number of subjects: 130
Study: 2070977

Group type: EXPERIMENTAL
Intervention: Multipolar probe
Number of subjects: 60

Group type: COMPARATOR
Intervention: Injection sclerosis
Number of subjects: 60
Study: 6131164

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Atenolol and Placebo
Number of subjects: 120
Study: 31487902

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback (EMG-BF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study: 28698133

Group type: EXPERIMENTAL
Intervention: Internal cooling
Number of subjects: 87
Study: 26538208

Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 mg daily for 8 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 24909996

Group type: EXPERIMENTAL
Intervention: Laser acupuncture alone (Group A)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Desmopressin alone (Group B)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Combined laser acupuncture and desmopressin (Group C)
Number of subjects: 186
Study: 22067280

Group type: COMPARATOR
Intervention: Control (CON) group received distance knowledge and distance feedback
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Experimental (EXP) group received neither distance knowledge nor feedback
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Experimental (EXP) group
Number of subjects: 22
Study: 19190916

Group type: EXPERIMENTAL
Intervention: 40 mg hyoscine N‐butylbromide (HBB)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1 mg glucagon
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of HBB and glucagon
Number of subjects: 10
Study: 17442581

Group type: EXPERIMENTAL
Intervention: Sleeve lobectomy (SL)
Number of subjects: 2984

Group type: EXPERIMENTAL
Intervention: Pulmonary artery reconstruction (PAR)
Number of subjects: 2984

Group type: COMPARATOR
Intervention: Pneumonectomy (PN)
Number of subjects: 2984
Study: 15576501

Group type: EXPERIMENTAL
Intervention: Loss-framed video emphasizing the costs of not detecting cervical cancer early
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Gain-framed video emphasizing the benefits of preventing cervical cancer
Number of subjects: 441
Study: 11843016

Group type: EXPERIMENTAL
Intervention: Professional interventions that enhance usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer support interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complementation of professional services with peer support from a mother experienced in breastfeeding
Number of subjects: 0
Study: 9428212

Group type: EXPERIMENTAL
Intervention: Intensive follow-up (yearly colonoscopy, liver CT, chest radiography, clinical review, and simple screening)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Standard follow-up (structured clinical review and simple screening tests only)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Yearly colonoscopy
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Liver CT
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Chest radiography
Number of subjects: 325
Study: 7646261

Group type: EXPERIMENTAL
Intervention: Post-exercise Doppler echocardiography in patients with chronic cardiac failure
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control population (healthy individuals)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Patients with chronic cardiac failure
Number of subjects: 17
Study: 2666139

Group type: EXPERIMENTAL
Intervention: SR‐Nicardipine 40 mg b.d.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 201593

Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Sarcoidosis patients
Number of subjects: 116

Group type: COMPARATOR
Intervention: Other diseases and normal subjects
Number of subjects: 116
Study: 29548285

Group type: COMPARATOR
Intervention: Pf-noPQ (no primaquine)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Pf-PQ1 (0.25 mg/kg primaquine)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Pv-noPQ (no primaquine)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Pv-PQ14 (14 days unsupervised 3.5 mg/kg primaquine)
Number of subjects: 309
Study: 27815344

Group type: EXPERIMENTAL
Intervention: SVG-DES (Drug-Eluting Stents)
Number of subjects: 125

Group type: COMPARATOR
Intervention: SVG-MT (Medical Treatment)
Number of subjects: 125
Study: 25691504

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Riluzole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23588127

Group type: EXPERIMENTAL
Intervention: Empiric antibiotic treatment
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 20297945

Group type: EXPERIMENTAL
Intervention: Disulfiram 800 mg twice a week for 26 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: No disulfiram (control group)
Number of subjects: 39
Study: 18355302

Group type: EXPERIMENTAL
Intervention: Levodopa therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gender, absolute levodopa dose, weight, disease duration, and initial motor Unified Parkinson's disease rating score
Number of subjects: 0
Study: 16434338

Group type: EXPERIMENTAL
Intervention: Bag-valve-mask ventilation with room air
Number of subjects: 40

Group type: COMPARATOR
Intervention: Resuscitation ventilator
Number of subjects: 40
Study: 14517770

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lean control group
Number of subjects: 40
Study: 10947990

Group type: EXPERIMENTAL
Intervention: Simultaneous visuo-tactile stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tactile stimulation
Number of subjects: 0
Study: 9005141

Group type: EXPERIMENTAL
Intervention: Argon diathermy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional diathermy
Number of subjects: 50
Study: 1521875

Group type: EXPERIMENTAL
Intervention: Prednisolone 0.8 mg/kg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 6150141

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31484571

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 646

Group type: COMPARATOR
Intervention: Normal weight
Number of subjects: 646

Group type: COMPARATOR
Intervention: Receiving HIV care from hospitals
Number of subjects: 646

Group type: COMPARATOR
Intervention: No telephone contact
Number of subjects: 646
Study: 29584548

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA101) plus Bendamustine (B); G 1,000 mg (days 1, 8, and 15, cycle 1; day 1, cycles 2 to 6) plus B 90 mg/m2/d (days 1 and 2, all cycles); G maintenance (1,000 mg every 2 months) for up to 2 years.
Number of subjects: 413

Group type: COMPARATOR
Intervention: Bendamustine monotherapy; B 120 mg/m2/d.
Number of subjects: 413
Study: 26641379

Group type: EXPERIMENTAL
Intervention: NO3-rich beetroot juice (BRJ)
Number of subjects: 13

Group type: COMPARATOR
Intervention: NO3-depleted beetroot juice (PLA)
Number of subjects: 13
Study: 24417786

Group type: EXPERIMENTAL
Intervention: CG100649 6 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CG100649 6 mg + ketoconazole 400 mg
Number of subjects: 30
Study: 23046564

Group type: EXPERIMENTAL
Intervention: 2.5 g/day of n-3 PUFA for 8 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 19890271

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (IVC)
Number of subjects: 84
Study: 17141978

Group type: EXPERIMENTAL
Intervention: Subcutaneous amifostine 500 mg (two 250-mg injections) before radiation therapy
Number of subjects: 54
Study: 16215334

Group type: EXPERIMENTAL
Intervention: Lance/squeeze (pain procedure)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Clustered Care (routine care giving task)
Number of subjects: 54
Study: 12147537

Group type: EXPERIMENTAL
Intervention: Patients successfully resuscitated after cardiac arrest
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Patients requiring vasopressor agents
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Patients analyzed for plasma endotoxin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Patients compared to healthy control subjects
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: In vitro plasma exchange between healthy control subjects and patients
Number of subjects: 61
Study: 10429602

Group type: EXPERIMENTAL
Intervention: Tourniquet released for hemostasis before wound closure
Number of subjects: 75

Group type: COMPARATOR
Intervention: Tourniquet released after wound closure
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tourniquet released for hemostasis before wound closure (subgroup of cementless prostheses)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Tourniquet released after wound closure (subgroup of cementless prostheses)
Number of subjects: 75
Study: 7482105

Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg single oral dose
Number of subjects: 103

Group type: COMPARATOR
Intervention: Clotrimazole 100 mg vaginal suppository twice a day for 3 days
Number of subjects: 103
Study: 2373576

Group type: EXPERIMENTAL
Intervention: 6 mg/kg caffeine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 mg/kg caffeine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (0 mg/kg caffeine)
Number of subjects: 30
Study: 7353458

Group type: EXPERIMENTAL
Intervention: ID glucose, 30-100 g (600-2000 ml/hr, 5% D/W)
Number of subjects: 5

Group type: COMPARATOR
Intervention: IV normal saline (200 ml/hr and 1000 ml/hr)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: IV glucose, 10 g (200 ml/hr, 5% D/W)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: IV glucose, 25 g (250 ml/hr, 10% D/W)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: IV glucose, 100 g (1000 ml/hr, 10% D/W)
Number of subjects: 5

Group type: COMPARATOR
Intervention: ID normal saline (1000 ml/hr)
Number of subjects: 5
Study: 29484510

Group type: EXPERIMENTAL
Intervention: Quranic therapy sessions
Number of subjects: 121
Study: 30822749

Group type: EXPERIMENTAL
Intervention: Whey Protein (WP)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Soy Protein (SP)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Carbohydrate (CHO)
Number of subjects: 17
Study: 28069062

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48634
Study: 25780262

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 6041

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 6041
Study: 22879453

Group type: EXPERIMENTAL
Intervention: Protein-energy supplementation (two 200-mL cans of commercial liquid formula providing additional 400 kcal of energy, 25g of protein, 9.4g of essential amino acids, 400mL of water) per day for 12 weeks
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Protein-energy supplementation
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 87
Study: 20952454

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 35